CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of small cell lung cancer.
  
  PURPOSE STATEMENT
  By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with small cell lung cancer.
  
  LEARNING OBJECTIVES

  • Understand up-to-date diagnostic and management strategies for small cell lung cancer (SCLC), including the roles of local therapy, chemotherapy and immunotherapy.
  • Review research findings with anti-PD-L1 antibodies in combination with platinum-based chemotherapy for previously untreated extensive-stage SCLC, and consider how these regimens are appropriately and safely integrated into clinical practice.
  • Counsel patients with progressive SCLC regarding personalized therapeutic decision-making, considering prior treatment, symptoms and other factors.
  • Recognize common side effects of systemic agents used for SCLC, and implement strategies to minimize and ameliorate them.
  • Recall the design of clinical trials evaluating other agents and strategies for SCLC, and counsel patients about availability and participation.

  ACCREDITATION STATEMENT
  Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
  
  CREDIT DESIGNATION STATEMENT
  NCPD credit is no longer available for this issue
  
  ONCC/ILNA CERTIFICATION INFORMATION
  NCPD credit is no longer available for this issue
  
  FOR SUCCESSFUL COMPLETION
  This NCPD activity consists of a video component.
  NCPD credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of NCPD activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Marianne J Davies, DNP, MSN, RN, APRN, CNS-BC, ACNP-BC, AOCNP, FAAN
  Nurse Practitioner
  Smilow Cancer Hospital at Yale New Haven
  Yale Comprehensive Cancer Center
  Associate Professor
  Yale University School of Nursing
  New Haven, Connecticut
  
  No relevant conflicts of interest to disclose.
  
  Matthew Gubens, MD, MS
  Associate Professor, Thoracic Medical Oncology
  University of California, San Francisco
  San Francisco, California
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, iTeos Therapeutics, Sanofi Genzyme, Surface Oncology; Contracted Research: Amgen Inc, Celgene Corporation, Johnson & Johnson Pharmaceuticals, Merck, Novartis, OncoMed Pharmaceuticals Inc, Trizell.
  
  Lowell L Hart, MD
  Scientific Director of Clinical Research
  Florida Cancer Specialists and Research Institute
  Fort Myers, Florida
  Associate Professor of Internal Medicine, Hematology and Oncology
  Wake Forest University School of Medicine
  Winston-Salem, North Carolina
  
  Advisory Committee: Boehringer Ingelheim Pharmaceuticals Inc, G1 Therapeutics Inc, Novartis; Speakers Bureau: Circulogene.
  
  Chaely J Medley, MSN, AGNP
  Oncology Nurse Practitioner
  Department of Thoracic Oncology
  UNC Lineberger Comprehensive Cancer Center
  Chapel Hill, North Carolina
  
  No relevant conflicts of interest to disclose.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.
  
  RTP NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for RTP have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from G1 Therapeutics Inc and Jazz Pharmaceuticals Inc.
  
  Release date: June 2022
  Expiration date: June 2023
  
  There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.